InMed Q2 FY2026 net loss $2.03M; cash drops to $7.0M; warns of material impact from pending US legislation on BayMedica

InMed Pharmaceuticals Inc.

2026-Q2 EPS reported -$0.95 revenue$1,940,309

Net loss of $2.03M for Q2 FY2026 (EPS -$0.51) vs net loss $2.58M in prior year; gross profit fell to $184K from $461K.
Cash and equivalents $7.0M at Dec 31, 2025 vs $11.1M at June 30, 2025; expects runway into Q4 calendar 2026.
BayMedica revenues $0.8M, down 26% YoY, due to pending US legislation H.R. 5371 that may prohibit certain cannabinoid sales after Nov 12, 2026.
INM-901 Alzheimer's candidate advanced: oral formulation showed robust bioavailability in large animal PK study; no adverse neural effects.
R&D expenses fell to $0.6M from $0.9M; expects substantial increase in H2 FY2026 for IND-enabling studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.